Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.

[1]  Y. Lotan,et al.  Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. , 2008, Urology.

[2]  Y. Lotan,et al.  1511: Outcomes of Patients with Clinical T1 Grade 3 Bladder Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy , 2007 .

[3]  G. Dalbagni,et al.  Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? , 2007, The Journal of urology.

[4]  Brian J. Smith,et al.  Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. , 2006, Urologic oncology.

[5]  S. Ohshima,et al.  Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: Significance of concomitant carcinoma in situ , 2004, International Urology and Nephrology.

[6]  D. Neal,et al.  Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. , 2002, The Journal of urology.

[7]  P. Russo,et al.  Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. O'Donnell,et al.  Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. , 2001, The Journal of urology.

[9]  Michael Cookson,et al.  Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. , 2001, The Journal of urology.

[10]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Almenar,et al.  The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. , 2000, The Journal of urology.

[12]  J. Beuth,et al.  Keyhole Limpet Hemocyanin for Carcinoma in situ of the Bladder: A Long-Term Follow-Up Study , 2000, European Urology.

[13]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[14]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[15]  R. Bahnson,et al.  Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. , 2000, The Journal of urology.

[16]  H. Grossman,et al.  Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. , 1998, The Journal of urology.

[17]  R. Sylvester,et al.  Factors affecting recurrence and progression in superficial bladder tumours. , 1995, European journal of cancer.

[18]  W. Fair,et al.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Michael Cookson,et al.  Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. , 1992, The Journal of urology.

[20]  M. LeBlanc,et al.  Relative risk trees for censored survival data. , 1992, Biometrics.

[21]  W. Catalona,et al.  Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. , 1985, The Journal of urology.